A University of Toronto startup that uses artificial intelligence to develop treatments for genetic diseases has forged a partnership with a U.S. biotechnology firm.

Deep Genomics, spun out of research done by computer science alumnus Professor Brendan Frey (PhD 1997) in the Faculty of Applied Science & Engineering (ECE), with cross-appointment to the department of computer science, said this week it will be working with Cambridge, Mass.-based, Wave Life Sciences to identify novel therapies for neuromuscular disorders – a category of illness that includes diseases like Duchenne muscular dystrophy.

Read the full story at U of T News.